A meta-analysis of 10 randomized trials found semaglutide reduced the risk of new-onset atrial fibrillation by 42% compared to placebo, regardless of route of administration or diabetes status.
42% AF risk reductionSemaglutide cut the risk of new-onset atrial fibrillation by nearly half across 12,651 patients in 10 randomized trials
What the researchers found
Semaglutide reduced incident atrial fibrillation by 42% (RR 0.58, 95% CI 0.40–0.85) with no heterogeneity across studies (I² = 0%). The benefit was consistent between oral semaglutide (RR 0.53) and subcutaneous semaglutide (RR 0.59), with no significant difference between routes (p = 0.83). Meta-regression showed no influence of diabetes proportion (p = 0.14) or BMI (p = 0.60) on the effect.
Why it matters
Atrial fibrillation is the most common heart rhythm disorder and a major cause of stroke. While GLP-1 drugs as a class show neutral arrhythmia effects, semaglutide specifically may reduce AF risk — adding another cardiovascular benefit beyond weight loss, blood sugar control, and heart failure reduction.
The numbers in context
Meta-analysis of RCTs in diabetic and non-diabetic patients at high cardiovascular risk.
How the study worked
Systematic review and meta-analysis of 10 randomized controlled trials. Included 12,651 patients (7,285 semaglutide, 5,366 placebo) with median follow-up of 68 months. Random-effects model used to pool relative risk. Subgroup analyses by route of administration and meta-regression for diabetes and BMI.
Who was studied
Diabetic and non-diabetic patients at high cardiovascular risk from RCTs
What this study cannot tell us
Post-hoc analysis of AF events from trials not specifically designed to study atrial fibrillation. AF events were not uniformly adjudicated across all trials. The mechanism behind the AF reduction is unclear. Long median follow-up (68 months) but individual trial durations varied. Predominantly high-CV-risk populations — may not apply to lower-risk patients.
How to read the evidence
Rated strong: meta-analysis of 10 randomized controlled trials with over 12,600 patients, zero heterogeneity, and consistent results across subgroups.
When this study was published
Published in 2024. Provides the most comprehensive pooled analysis of semaglutide and atrial fibrillation risk to date.
The bigger picture
Semaglutide continues to accumulate cardiovascular benefits beyond its original diabetes indication. A 42% reduction in atrial fibrillation adds to its effects on heart failure, major cardiac events, and kidney protection, making it one of the most broadly cardioprotective drugs available.
Questions still open
- What is the mechanism by which semaglutide reduces atrial fibrillation?
- Is this benefit truly semaglutide-specific or would other GLP-1 drugs show similar effects in larger studies?
- Would semaglutide prevent AF in patients without diabetes or high cardiovascular risk?
Common questions
Does semaglutide protect against atrial fibrillation?
Is the atrial fibrillation benefit unique to semaglutide?
Read the original research
Glucagon-like peptide-1 receptor agonist semaglutide reduces atrial fibrillation incidence: A systematic review and meta-analysis.
European journal of clinical investigation, 54(12), e14292
Citation
Saglietto, Andrea; Falasconi, Giulio; Penela, Diego; Francia, Pietro; Sau, Arunashis; Ng, Fu Siong; Dusi, Veronica; Castagno, Davide; Gaita, Fiorenzo; Berruezo, Antonio; De Ferrari, Gaetano Maria; Anselmino, Matteo. (2024). Glucagon-like peptide-1 receptor agonist semaglutide reduces atrial fibrillation incidence: A systematic review and meta-analysis.. European journal of clinical investigation, 54(12), e14292. https://doi.org/10.1111/eci.14292